Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

Whats Happening:

Supira Medical, a clinical-stage Shifamed portfolio company, has successfully raised $120 million in an oversubscribed Series E financing round. The funds will be used to accelerate the development of their percutaneous ventricular assist device (pVAD) for high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock patients. The company has also completed enrollment in its U.S. SUPPORT I Early Feasibility Study, evaluating the safety and feasibility of their pVAD in HRPCI patients.

Key Moves:

• Supira Medical raises $120M in oversubscribed Series E financing

• Funds to accelerate clinical programs for HRPCI and cardiogenic shock

• Completion of enrollment in SUPPORT I Early Feasibility Study

By The Numbers:

• $120M raised in Series E financing

• 15 patients enrolled in SUPPORT I Early Feasibility Study

• 85 HRPCI patients have benefited from the Supira System to date

Key Quotes:

• "We are grateful for the continued confidence and support from our current investors and delighted to welcome new world-class investors to this financing consortium," - Dr. Nitin Salunke, President and CEO of Supira Medical

• "We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients," - Dr. Christopher Shen, Partner, Novo Holdings US

Bottom Line:

Supira Medical's successful $120M Series E financing and completion of the SUPPORT I Early Feasibility Study mark significant milestones in the development of their innovative pVAD technology. This funding and clinical progress position the company to potentially transform the treatment landscape for high-risk percutaneous coronary intervention and cardiogenic shock patients, addressing a critical unmet need in cardiovascular care.

Read Full Article